Mountain Pacific Investment Advisers Inc. ID increased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 3.5% during the first quarter, Holdings Channel reports. The firm owned 14,938 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the period. Mountain Pacific Investment Advisers Inc. ID’s holdings in Pfizer were worth $511,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Ashburton Jersey Ltd acquired a new stake in shares of Pfizer during the third quarter valued at about $1,726,000. SevenBridge Financial Group LLC boosted its stake in shares of Pfizer by 26.3% in the third quarter. SevenBridge Financial Group LLC now owns 83,458 shares of the biopharmaceutical company’s stock valued at $2,734,000 after buying an additional 17,386 shares in the last quarter. Mcmillion Capital Management Inc. boosted its stake in shares of Pfizer by 3.4% in the third quarter. Mcmillion Capital Management Inc. now owns 96,431 shares of the biopharmaceutical company’s stock valued at $3,266,000 after buying an additional 3,144 shares in the last quarter. RGT Capital Management Ltd. acquired a new stake in shares of Pfizer during the third quarter valued at about $898,000. Finally, TrueNorth Inc. acquired a new stake in shares of Pfizer during the third quarter valued at about $928,000. 70.82% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer, Inc. (NYSE:PFE) opened at 32.97 on Friday. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $37.39. The stock’s 50 day moving average is $32.73 and its 200-day moving average is $33.02. The stock has a market capitalization of $196.76 billion, a price-to-earnings ratio of 27.75 and a beta of 1.02.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a net margin of 13.76% and a return on equity of 23.68%. The business’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. On average, equities research analysts expect that Pfizer, Inc. will post $2.55 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 1st. Investors of record on Friday, May 12th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.88%. The ex-dividend date was Wednesday, May 10th. Pfizer’s payout ratio is currently 108.48%.

TRADEMARK VIOLATION WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/mountain-pacific-investment-advisers-inc-id-has-511000-stake-in-pfizer-inc-pfe-3/1371852.html.

Several brokerages have recently issued reports on PFE. Citigroup Inc. cut shares of Pfizer from a “neutral” rating to a “sell” rating and decreased their target price for the company from $38.00 to $31.00 in a research report on Tuesday, May 16th. Jefferies Group LLC set a $34.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Thursday, March 9th. Sanford C. Bernstein set a $35.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $33.68 target price on the stock. in a research report on Monday, March 13th. Finally, Credit Suisse Group set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $37.32.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.